Frontlight ResearchEarly access
Childhood cancers trials in Brazil
22 of 32 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Where
- São Paulo
- Age
- 6 months to 17 years
- People
- 370 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00 - Phase 3Taking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Barretos, Belo Horizonte, Curitiba, Fortaleza, Goiânia, Ijuí, Natal, Porto Alegre, Porto Velho, Recife, Rio de Janeiro, Salvador, São Paulo, Teresina
- Age
- 15 years and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Barretos, Rio de Janeiro, São Paulo
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 4CompletedAsciminib Roll-over Study
- Where
- Rio de Janeiro, São Paulo
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 2Not yet taking people in BrazilTarget Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
- Where
- São Paulo
- Age
- 1 year to 39 years
- People
- 30 worldwide
- Run by
- University of California, San Francisco
See details and how to joinNCT07226453 - Phase 1/2Taking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Curitiba, São Paulo
- Age
- 6 months to 30 years
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - Phase 1/2Taking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Brasília, Natal, Rio de Janeiro, São Paulo
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - Phase 2Taking peopleEntrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
- Where
- Barretos, São Paulo
- Age
- Up to 3 years
- People
- 52 worldwide
- Run by
- St. Jude Children's Research Hospital
See details and how to joinNCT06528691 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Barretos, Curitiba, Porto Alegre, São José do Rio Preto
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Barretos, Fortaleza, Jaú, Porto Alegre, São Paulo
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - Phase 1/2SuspendedAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Where
- Porto Alegre, São Paulo
- Age
- 12 years and over
- People
- 255 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00 - Phase 1/2Not yet taking people in BrazilAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- São Paulo
- Age
- 12 years and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00 - Phase 1/2Taking peopleA Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Where
- Barretos, Porto Alegre, São José do Rio Preto
- Age
- 1 month to 17 years
- People
- 50 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06941272 · EU 2024-518771-66-00 - Phase 2Not yet taking people in BrazilA Study of Propranolol to Treat Kaposi Sarcoma
- Where
- Rio de Janeiro, Salvador
- People
- 25 worldwide
- Run by
- AIDS Malignancy Consortium
See details and how to joinNCT05797662 - Phase 2Taking peopleNaxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Where
- São Paulo
- Age
- 12 months to 21 years
- People
- 93 worldwide
- Run by
- Giselle Sholler
See details and how to joinNCT05489887 · EU 2025-524140-35-00 - Phase 3Taking peopleONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
- Where
- São Paulo
- People
- 510 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05580562 · EU 2022-502051-56-00 - Phase 1Taking peopleClinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
- Where
- São Paulo
- Age
- 2 years to 70 years
- People
- 30
- Run by
- Nelson Hamerschlak
See details and how to joinNCT05705570 - Phase 2Taking peopleReal-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
- Where
- São Paulo
- Age
- 14 years and over
- People
- 100
- Run by
- José Claudio Casali da Rocha
See details and how to joinNCT07167329 - Phase 2Taking peopleBortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
- Where
- São Paulo
- Age
- 16 years to 60 years
- People
- 50
- Run by
- Instituto do Cancer do Estado de São Paulo
See details and how to joinNCT06034561 - Phase 2Taking peopleSafety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
- Where
- Porto Alegre, São Paulo
- People
- 130 worldwide
- Run by
- Population Health Research Institute
See details and how to joinNCT04680442 - Phase 1/2Taking peopleCD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma
- Where
- Campinas, Ribeirão Preto, São Paulo
- Age
- 3 years to 70 years
- People
- 81
- Run by
- University of Sao Paulo
See details and how to joinNCT06101381 - Phase 2Taking peopleEverolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
- Where
- São Paulo
- Age
- 16 years and over
- People
- 100
- Run by
- AC Camargo Cancer Center
See details and how to joinNCT06472388